Regeneron Enrolls First Patient in Study of VEGF Trap-Eye to Treat Central Retinal Vein Occlusion
Links shared publicly online about this topic.
- 1,858total visits
Regeneron Enrolls First Patient in Study of VEGF Trap-Eye to Treat Central Retinal Vein Occlusion
Regeneron has announced that the first patient was enrolled in its Phase 3 CRVO program; this triggered a $20 million payment from Bayer.
View full resource at eyedocnews.com
Tags: Circulation, Bayer
Most Recently Shared on July 31, 2009 at 5:41 am By:
Discuss: Regeneron Commence Study of VEGF Trap-Eye for CVRO Treatment: By Dr. Dominique Walton BrooksReg.. http://bit.ly/OlnoR
Advertisement
